Predictive Value of the nProfiler 1 Assay for the Efficacy of Adjuvant S-1–Based Doublet Chemotherapy in Stage III Gastric Cancer: A Post-Hoc Analysis of a Randomized Phase III Trial
Cancer Research and Treatment · 2025
DOI: 10.4143/crt.2024.705 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Cancer Research and Treatment, 2025. Verfasst von Dong Ki Lee und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Stomach Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
The nProfiler 1 Stomach Cancer Assay (nProfiler1), designed to predict responses to fluorouracil-based adjuvant chemotherapy, measures the expression of four gastric cancer target genes (GZMB, WARS, SFRP4, and CDX1). The randomized phase III POST trial aimed to compare the efficacies of two adjuvant S-1-based doublet chemotherapies: S-1 plus cisplatin (SP) and S-1 plus docetaxel (DS). This study aimed to validate the nProfiler1 assay using a distinct cohort from the POST trial.Materials and Methods The nProfiler1 assay stratifies patients into three groups (low-risk, intermediate-risk, and high-risk) using the prognostic single-patient classifier and two groups (chemotherapy-benefit and no-benefit) using the predictive single-patient classifier. The nProfiler1 assay was applied to formalin-fixed paraffin-embedded slides obtained from the POST trial. Disease-free survival (DFS) and overall survival (OS), including 5-year survival rates, were calculated for the enrolled patients.
Results
Of the 153 patients in the POST trial, 118 were included in the post-hoc analysis. With a median follow-up of 57.9 months, no significant difference in DFS or OS was observed between the SP and DS groups. The prognostic single-patient classifier predicted the OS in the SP group (p=0.043) but not in the DS group (p=0.594). The chemotherapy-benefit group exhibited numerically longer DFS than the no-benefit group in the SP and DS groups.
Conclusion
The nProfiler1 assay offers valuable insights into the prognosis and efficacy of adjuvant chemotherapy based on fluorouracil plus platinum doublet regimens but not docetaxel-containing regimens. Further validation with larger patient cohorts and different regimens is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Yonsei University College of Medicine, Seoul, Korea.
- Divison of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
- Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Korea.
- Division of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
- Division of Hematology-Oncology, Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang, Korea.
- Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, Korea.
Zitieren
APA
Lee, D. K., Lee, C. K., Kim, H. S., Sym, S. J., Zang, D. Y., Kim, K. H., Lim, J. H., Kim, H. S., Lee, K. H., Gee, H. Y., Rha, S. Y., Kim, H., & Jung, M. (2025). Predictive Value of the nProfiler 1 Assay for the Efficacy of Adjuvant S-1–Based Doublet Chemotherapy in Stage III Gastric Cancer: A Post-Hoc Analysis of a Randomized Phase III Trial. Cancer Research and Treatment. https://doi.org/10.4143/crt.2024.705
Vancouver
Lee DK, Lee CK, Kim HS, Sym SJ, Zang DY, Kim KH, et al. Predictive Value of the nProfiler 1 Assay for the Efficacy of Adjuvant S-1–Based Doublet Chemotherapy in Stage III Gastric Cancer: A Post-Hoc Analysis of a Randomized Phase III Trial. Cancer Research and Treatment. 2025. doi:10.4143/crt.2024.705
BibTeX
@article{Lee2025,
author = {Lee, Dong Ki and Lee, Choong-Kun and Kim, Hyo Song and Sym, Sun Jin and Zang, Dae Young and Kim, Ki Hyang and Lim, Joo Han and Kim, Hae Su and Lee, Kyung Hee and Gee, Heon Yung and Rha, Sun Young and Kim, Hyunki and Jung, Minkyu},
title = {Predictive Value of the nProfiler 1 Assay for the Efficacy of Adjuvant S-1–Based Doublet Chemotherapy in Stage III Gastric Cancer: A Post-Hoc Analysis of a Randomized Phase III Trial},
journal = {Cancer Research and Treatment},
year = {2025},
doi = {10.4143/crt.2024.705}
}
EUVIMED